Rebamipide (systemic; 300 mg daily) vs placebo
Global aphthae count and pain score · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
- Matsuda 2003 (rebamipide 300 mg daily vs placebo, 35 patients; high risk of reporting bias; concomitant treatments): authors stated that rebamipide improved the global evaluation aphthae count and global evaluation…1 study · 35 participantsGRADE not reported